Business Context and Reporting Period
Company: Grifols, S.A. (Spanish holding company for the Grifols Group)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Fiscal year ended December 31, 2025
Filing Date: February 26, 2026
Business Overview: The Company acts as the parent entity, providing administration, management, and control services to subsidiaries. Its primary revenue sources are leasing owned buildings to Group companies, rendering centralized services (IT, HR, marketing), and receiving dividends and interest from subsidiaries. The Company does not conduct its own R&D activities.
Key Financial Metrics (Year Ended Dec 31, 2025)
| Metric | 2025 (€'000) | 2024 (€'000) |
|---|---|---|
| Total Revenues | 1,228,740 | 701,053 |
| Profit for the Year | 192,054 | (83,138) |
| Profit Before Tax | 168,358 | (75,455) |
| Total Assets | 12,655,759 | 12,840,036 |
| Total Equity | 1,973,131 | 1,953,852 |
| Cash and Cash Equivalents | 1,233 | 1,283 |
| Operating Cash Flow | 307,984 | (397,463) |
| Dividends Paid (Interim) | (102,076) | — |
Note: Figures are expressed in thousands of Euros. The 2025 profit includes a significant reversal of impairment losses on investments.
Material Changes vs. Prior Period
- Turnaround in Profitability: The Company moved from a net loss of €83.1 million in 2024 to a net profit of €192.1 million in 2025. This is primarily driven by a €35.9 million net reversal of impairment losses on investments (notably Laboratorios Grifols, S.A.) compared to €9.9 million in impairment losses in 2024.
- Revenue Growth: Total revenues increased by 75% to €1.23 billion. This surge is largely attributable to a massive increase in finance income (€548.3 million in 2025 vs. €445.8 million in 2024) and dividends received (€400.6 million in 2025 vs. €7.4 million in 2024).
- Dividend Distribution: An interim dividend of €102.1 million was declared and paid in 2025, whereas no dividends were paid in 2024.
- Investment Portfolio: Significant capitalization of loans to subsidiaries occurred in 2025 (e.g., €500 million to Grifols Worldwide Op. Ltd.), increasing the carrying amount of investments without impacting the income statement.
Guidance, Outlook, Risks, and Contingencies
- Outlook: Management states the Group's treasury budget anticipates meeting all commitments in the next 12 months. The Company has financing alternatives including debt market access and potential divestments of non-strategic assets.
- Risks:
- Regulatory & Tax: Ongoing tax audits in Spain (2017-2025) and other jurisdictions regarding transfer pricing and VAT. A net tax liability of €93.1 million is recognized for uncertain tax positions.
- Legal Proceedings: An administrative sanctioning procedure by the CNMV (Spanish securities regulator) concluded in June 2025 with a proposed sanction not exceeding €1 million; an appeal is pending before the National High Court. Additionally, squeeze-out proceedings regarding Biotest AG are pending a final decision by the Federal Court of Justice in Germany.
- Financial Covenants: The Credit Agreement includes a leverage ratio covenant (max 7.00:1.00), which was not applicable in 2025 as the Revolving Credit Facility was undrawn.
- Unusual Items: The 2024 financials included a one-time gain of €246.7 million from the sale of a 20% stake in Shanghai RAAS Blood Products Co., Ltd. (SRAAS). In 2025, the remaining 6.58% stake is classified as a financial asset at fair value through equity.
Investor Verification Checklist
- Dividend Sustainability: Verify the source of the €400.6 million in dividend income and the €102.1 million interim dividend payout against the consolidated cash flow of the Group, as the Parent Company's own cash balance is low (€1.2 million).
- Impairment Reversals: Scrutinize the assumptions used for the €35.9 million reversal of impairment losses, particularly for Laboratorios Grifols, S.A., to ensure they are not overly optimistic regarding future cash flows.
- Tax Exposure: Review the details of the €93.1 million provision for uncertain tax positions and the status of the Spanish tax audits (2017-2025) to assess potential future cash outflows.
- Related Party Transactions: Confirm the arm's-length nature of the €548.3 million in finance income and €4.1 billion in loans to Group companies, which dominate the balance sheet.
- Debt Structure: Monitor the maturity profile of the €5.3 billion in promissory notes and the €878 million in loans/borrowings, noting the high interest rates on recent issuances (7.125% - 7.5%).